Adagrasib with cetuximab for treating advanced colorectal cancer with KRAS G12C mutation after 1 therapy

Adagrasib in combination with cetuximab is being developed as a treatment for advanced or metastatic colorectal cancer (CRC) with a KRAS G12C mutation who have had one prior treatment. CRC, which is also called bowel cancer, starts to form in the colon and the rectum. Normal cells in the colon or rectum turn into abnormal growths (polyps). Over time, the polyps accumulate damage and grow uncontrollably. The cancer can spread to other parts of the body, this is then known as metastatic CRC. Advanced CRC means the cancer has grown beyond the colon or rectum and spread to other organs. At this stage, it’s harder to treat because the cancer is no longer just in one place but has travelled through the body. KRAS G12C is a common genetic change in CRC that helps the cancer grow. It affects up to 50% of CRC patients and is hard to treat with medicine. Therefore, there is a need for treatments that extend survival and maintain quality of life for patients with advanced KRAS G12C mutated CRC.